HIV infected patients whose treatment is delayed not only become sicker than those treated earlier, but also require tens of thousands of dollars more in care over the first several years of their treatment.
Most patients who take anti-depressants give up their treatment in less than six months, the minimum period recommended for treating severe depression and only 25% continue their treatment for more than 11 months.
Boston University researchers have developed a simple diagnostic tool that can quickly identify dangerous viruses like Ebola and Marburg. The biosensor is the size of a quarter and can detect viruses in a blood sample.
Researchers at Virginia Commonwealth University have discovered that a gene well known for its involvement in tumor cell development, growth and metastasis also protects cancer cells from being destroyed by chemotherapy.
Reinnervate has announced the first commercial launch of alvetex, its 3D cell culture technology. Alvetex provides a robust and inert scaffold for cells to grow and form complex 3D cell structures, mimicking the normal growth and formation of tissues.
Thermo Fisher Scientific Inc. has introduced the ThermoChill I and ThermoChill II re-circulating chillers. These compact, floor-standing re-circulating chillers provide a temperature range of 5 to 30°C and have a cooling capacity from 700 to 2000 W.
Researchers at Harvard Medical School and the Harvard School of Dental Medicine have found that by mimicking a rare genetic disorder in a dish, they can rewind the internal clock of a mature cell and drive it back into an adult stem-cell stage.
Researchers have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body.
Trana Discovery, Inc., announced that its anti-HIV 201 HTS Drug Discovery Assay and the Staphylococcus aureus Antibiotic Drug Discovery Assay, qualified to receive federal grant funding under the Patient Protection and Affordable Care Act.
Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease progression in patients with type 2 diabetic nephropathy.
Omthera Pharmaceuticals, Inc. has reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the design of its Phase 3 registration clinical trial of Epanova, for the treatment of patients with very high triglycerides.
AIDS patients in South Africa are being robbed of their lifesaving drugs so that they can be mixed with marijuana and smoked, authorities and health experts say. The concoction is called "whoonga" and it adds a bizarre twist to the war on AIDS.
It began as a rumor that farmers saw waste from a U.N. peacekeeping base flow into a river. Within days of the talk, hundreds downstream had died from cholera.
PRA International announced the opening a new bioanalytical laboratory in Lenexa, Kan., to support the company’s early-phase study capabilities in the United States.
Porvair Sciences Ltd. has announced that a leading manufacturer of ready-made oligonucleotides, with bases in both North America and Europe, has standardized on their Ultravap Blowdown Station for careful drying of their production samples.